Non Exudative AMD Imaged With SS-OCT- Extension

Description

The investigators wish to better understand the role of the choriocapillaris (CC) in the formation and progression of non-exudative in age related macular degeneration (armd) by imaging the retinal pigment epithelium (rpe) and the choroidal microvasculature and by studying their inter-dependence to determine if the loss of the CC could prove useful as an anatomic clinical trial endpoint in future drug trials.

Conditions

Dry Macular Degeneration

Talk to us

Study Overview

On this page

Study Details

Study overview

The investigators wish to better understand the role of the choriocapillaris (CC) in the formation and progression of non-exudative in age related macular degeneration (armd) by imaging the retinal pigment epithelium (rpe) and the choroidal microvasculature and by studying their inter-dependence to determine if the loss of the CC could prove useful as an anatomic clinical trial endpoint in future drug trials.

Non Exudative Age-Related Macular Degeneration Imaged With Swept Source Optical Coherence Tomography: The Extension Study

Non Exudative AMD Imaged With SS-OCT- Extension

Condition
Dry Macular Degeneration
Intervention / Treatment

-

Contacts and Locations

Los Angeles

University of California Los Angeles Doheny Eye Institute, Los Angeles, California, United States, 91105

Miami

Bascom Palmer Eye Institue, Miami, Florida, United States, 33136

Boston

New England Eye Center/Tufts Medical Center, Boston, Massachusetts, United States, 02111

New York

Vitreous Retina Macular Consultants of NY, New York, New York, United States, 10022

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Enrollment in and completion of the BIRC-01 study
  • * Clinic diagnosis of non-exudative iAMD in at least one eye with a drusen volume in the central 3 mm circle centered on the fovea of at least 0.02 mm3 in the absence of GA or nGA as diagnosed with OCT en face imaging OR Clinical diagnosis of early or early/intermediate stage AMD in one eye in the absence of nGA or GA and exudative AMD in the other eye OR clinical diagnosis of GA or nGA secondary to AMD that is at least the size of a large druse (125 microns in diameter; 0.05 mm2) and no greater than 7 disc areas (17 mm2) in at least one eye which has never been treated with anti-VEGF agents
  • * Willing and able to comply with clinic visits and study-related procedures
  • * Provide signed informed consent
  • * Subjects with exudative AMD in both eyes
  • * Eyes with evidence of non-proliferative and proliferative diabetic retinopathy.
  • * Presence of confounding ocular diagnosis such as myopia \>6D, or other ocular conditions that may cause retinal pigment epithelium atrophy or exudative MNV
  • * Subjects currently or previously enrolled in other interventional clinical trials in which treatment was administered to the study eye.
  • * Previous vitrectomy or intravitreal injections in the study eye.
  • * Axial length measurement ≥ 26 mm.
  • * Subjects unable to give informed consent.
  • * Subjects who are unable to comply with imaging guidelines

Ages Eligible for Study

to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Boston Image Reading Center,

Nadia Waheed, MD, PRINCIPAL_INVESTIGATOR, Boston Image Reading Center/Tufts Medical Center

Philip Rosenfield, MD, PhD, PRINCIPAL_INVESTIGATOR, Bascom Palmer Eye Institute

Study Record Dates

2025-08